The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.
Hamdouchi, C., Keyser, H., Collins, E., Jaramillo, C., De Diego, J.E., Spencer, C.D., Dempsey, J.A., Anderson, B.D., Leggett, T., Stamm, N.B., Schultz, R.M., Watkins, S.A., Cocke, K., Lemke, S., Burke, T.F., Beckmann, R.P., Dixon, J.T., Gurganus, T.M., Rankl, N.B., Houck, K.A., Zhang, F., Vieth, M., Espinosa, J., Timm, D.E., Campbell, R.M., Patel, B.K., Brooks, H.B.(2004) Mol Cancer Ther 3: 1-9
- PubMed: 14749470 
- Primary Citation of Related Structures:  
1PYE - PubMed Abstract: 
The protein kinase family represents an enormous opportunity for drug development. However, the current limitation in structural diversity of kinase inhibitors has complicated efforts to identify effective treatments of diseases that involve protein kinase signaling pathways ...